Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the application:

- 1. (currently amended) A method of treating stroke in a human who has undergone a stroke at least three hours earlier, said method comprising delivering about at least 6 million viable hNT neuronal cells within three hours of cell preparation to a plurality of brain area sites involved in the stroke wherein the cells are delivered in at least one tract to an area inferior to the stroke, within the midportion of the stroke and to an area superior to the stroke.
- 2. (previously presented) The method of claim 1 further comprising the step of <u>delivering</u> the cells to more than one tract wherein each tract is spaced between about 5 mm and 6 mm from the target stroke area using a twist drill or a burr to provide entry through the skull through which the cells can be delivered into the brain.
- 3. (canceled)
- 4. (original) The method of claim 1 wherein the stroke has taken place at least three months earlier.
- 5. (canceled)
- 6. (canceled)
- 7. (currently amended) A method of improving speech in a person who has experienced brain damage due to a stroke which interferes with speech, said method comprising injecting a sterile composition of about at least 6 million hNT neuronal cells within three hours of cell preparation into a plurality of brain sites affected by stroke wherein the cells are injected in at least one tract to an area inferior to the stroke, within the midportion of the stroke and to an area superior to the stroke.
- 8. (canceled)
- 9. (canceled)
- 10. (currently amended) A method of improving motor performance in a person who has experienced brain damage due to a stroke which interferes with movement, said method comprising injecting a sterile composition of about at least 6 million hNT neuronal cells within three hours of cell preparation into a plurality of sites of the brain sites affected by

stroke wherein the cells are injected in at least one tract to an area inferior to the stroke, within the midportion of the stroke and to an area superior to the stroke.

- 11. (canceled)
- 12. (previously presented) The method of claim 10, wherein the injected hNT neuronal cells are a sterile composition of hNT human neuronal cells.
- 13. (currently amended) A method of improving cognition in a person who has experienced stroke-induced brain damage which interferes with cognition, said method comprising delivering a sterile composition of about-at least 6 million hNT neuronal cells within three hours of cell preparation into a plurality of sites of the brain sites affected by stroke wherein the cells are delivered in at least one tract to an area inferior to the stroke, within the midportion of the stroke and to an area superior to the stroke.
- 14. (currently amended) A method of improving sensory function in a person who has experienced stroke-induced brain damage which interferes with sensation, said method comprising delivering a sterile composition of about at least 6 million hNT neuronal cells within three hours of cell preparation to a plurality of sites of the central nervous system or to the cerebral spinal fluid.
- 15. (currently amended) A method of improving sensory, motor or cognitive function in a person who has experienced brain damage due to a stroke which interferes with those functions, said method comprising delivering a sterile composition of about at least 6 million hNT neuronal cells within three hours of cell preparation into a plurality of locations from which the hNT neuronal cells migrate to the damaged area.
- 16. (previously presented) The method of claim 14, comprising delivering the composition into the cisternae.
- 17. (currently amended) A method of replacing in a human's nervous system nerves lost to a stroke, the method comprising administering to the human a sterile composition of about at least 6 million hNT neuronal cells within three hours of cell preparation to a plurality of sites in the brain.
- 18. (canceled)
- 19. (previously presented) The method of claim 15 wherein cells are concomitantly administered with the hNT neuronal cells and the cells are selected from neural stem cells, HCN1 cells, fetal non-human mammalian cells, neural crest cells or a combination

thereof.

20. (currently amended) A method of treating morbidity in a human due to stroke, resulting in at least one of a decrease in cognitive function, motor function, sensory function and speech function, said method comprising:

administering to at least one brain site within the infarct site of said stroke in said human a number of <u>neuronal</u> <u>neural</u> cells <u>within three hours of cell preparation</u>, wherein said stroke occurred at least three hours prior to said administration, and

wherein said number is <u>about</u> <u>at least</u> 6 million, whereby over a period of at least one year, said morbidity is lessened.

- 21. (canceled)
- 22. (currently amended) The method of claim 20, wherein said neural cells are delivered to at least one tract in an area inferior to the stroke, within the midportion of the stroke and in an area superior to the stroke more than one site in the area of the infarct caused by said stroke.
- 23. (cancelled)
- 24. (previously presented) The method of claim 20, wherein said cells are delivered to said brain site via stereotactic injection.
- 25. (previously presented) The method of claim 20, wherein said reduction in morbidity is comprised in a reduction in decrease in cognitive function, or a reduction in decrease in motor function, or a reduction in decrease in sensory function or a reduction in decrease in speech function as opposed to a corresponding decrease observed in said human prior to said administering and following said stroke.
- 26. (previously presented) The method of claim 20, wherein after said period, nerves lost in said infarct site are regrown.
- 27. (previously presented) The method of claim 20, wherein said neural cells are non-immunogenic, non-tumorigenic, and synapse with local neurons following injection.
- 28. (previously presented) The method of claim 27, wherein said neural cells comprise at least one of hNT neuronal cells, HCN-1 cells, fetal pig cells and neural crest cells.
- 29. (currently amended) The method of claim 20, wherein said neuronal neural cells are administered together with macrophages activated by exposure to peripheral nerve cells, so as to improve nerve regeneration by said neuronal neural cells.

- 30. (previously presented) The method of claim 20, wherein said stroke occurred at least three months prior to said administering.
- 31. (new) The method of claim 22 further comprising the step of delivering the cells to more than one tract wherein each tract is spaced between about 5 mm and 6 mm from the target stroke area.